Research at the Penn Sjögren's Syndrome Center
In addition to clinical excellence, the Center also supports clinical and basic research. Physicians at Penn Presbyterian pioneered the development of a nuclear medicine test for Sjögren's syndrome called salivary scintigraphy.
Studies are ongoing to determine the diagnostic and prognostic value of this technique. Some of the original research work for pilocarpine (Salagen), the first prescription medication ever FDA approved for Sjögren's syndrome, was also conducted at Penn Presbyterian.